AR061887A1 - Una composicion de vacuna contra el dengue - Google Patents
Una composicion de vacuna contra el dengueInfo
- Publication number
- AR061887A1 AR061887A1 ARP070103083A ARP070103083A AR061887A1 AR 061887 A1 AR061887 A1 AR 061887A1 AR P070103083 A ARP070103083 A AR P070103083A AR P070103083 A ARP070103083 A AR P070103083A AR 061887 A1 AR061887 A1 AR 061887A1
- Authority
- AR
- Argentina
- Prior art keywords
- vaccine
- composition
- serotype
- dose
- dengue virus
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 8
- 208000001490 Dengue Diseases 0.000 title abstract 2
- 206010012310 Dengue fever Diseases 0.000 title abstract 2
- 208000025729 dengue disease Diseases 0.000 title abstract 2
- 241000725619 Dengue virus Species 0.000 abstract 5
- 241000710829 Dengue virus group Species 0.000 abstract 1
- 229940001442 combination vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicacion 1: Una composicion de vacuna que comprende (i) una dosis de un virus del dengue vacunal de un primer serotipo y una dosis de un virus del dengue vacunal de un segundo serotipo y (ii) una dosis de un virus del dengue vacunal de un tercer serotipo y una dosis de un virus del dengue vacunal de un cuarto serotipo, como composicion de vacuna de combinacion contra el dengue para la administracion sucesiva, en la cual los virus del dengue vacunales (ii) se administran por lo menos 30 días y a lo sumo 1 ano después de la administracion de lo virus del dengue vacunal (i).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0606324A FR2903605A1 (fr) | 2006-07-12 | 2006-07-12 | Methode d'immunisation contre les quatres serotypes de la dengue |
Publications (1)
Publication Number | Publication Date |
---|---|
AR061887A1 true AR061887A1 (es) | 2008-10-01 |
Family
ID=37866217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070103083A AR061887A1 (es) | 2006-07-12 | 2007-07-11 | Una composicion de vacuna contra el dengue |
Country Status (16)
Country | Link |
---|---|
US (2) | US7718357B2 (es) |
EP (1) | EP2043680A1 (es) |
JP (1) | JP5295956B2 (es) |
KR (1) | KR20090027759A (es) |
CN (1) | CN101489585B (es) |
AR (1) | AR061887A1 (es) |
AU (1) | AU2007274100B2 (es) |
BR (1) | BRPI0712878A2 (es) |
CA (1) | CA2656349A1 (es) |
FR (1) | FR2903605A1 (es) |
IL (1) | IL196331A0 (es) |
MX (1) | MX2009000369A (es) |
MY (1) | MY169275A (es) |
TW (1) | TWI400333B (es) |
WO (1) | WO2008007021A1 (es) |
ZA (1) | ZA200900155B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2618783A1 (en) * | 2005-08-10 | 2007-02-22 | Acambis Inc. | Vaccination against dengue virus infection |
FR2906724B1 (fr) * | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
FR2909286B1 (fr) * | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
CN101959527B (zh) | 2008-03-05 | 2016-04-20 | 赛诺菲巴斯德有限公司 | 一种使含佐剂的疫苗组合物稳定的方法 |
EP2143440A1 (fr) * | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
EP2473624B1 (en) | 2009-08-31 | 2019-05-01 | Gen-Probe Incorporated | Dengue virus assay |
SG10201508700XA (en) | 2010-10-29 | 2015-11-27 | Merck Sharp & Dohme | Recombinant subunit dengue virus vaccine |
CA2878599A1 (en) | 2012-07-24 | 2014-01-30 | Jiansheng Yao | Vaccine compositions for prevention against dengue virus infection |
SG11201500412TA (en) | 2012-07-24 | 2015-02-27 | Sanofi Pasteur | Vaccine compositions |
WO2014083194A1 (en) | 2012-11-30 | 2014-06-05 | Sanofi Pasteur | Methods for inducing antibodies |
TW201620546A (zh) | 2014-09-02 | 2016-06-16 | 賽諾菲巴斯德公司 | 疫苗組合物 |
WO2017005652A1 (en) | 2015-07-03 | 2017-01-12 | Sanofi Pasteur | Concomitant dengue and yellow fever vaccination |
US11690903B2 (en) | 2017-10-05 | 2023-07-04 | Sanofi Pasteur | Compositions for booster vaccination against dengue |
SG11202102104SA (en) | 2018-09-05 | 2021-04-29 | Takeda Vaccines Inc | Dengue vaccine unit dose and administration thereof |
EP4013451A1 (en) | 2019-08-16 | 2022-06-22 | Takeda Vaccines, Inc. | Methods for preventing dengue and hepatitis a |
US20240076631A2 (en) | 2020-02-27 | 2024-03-07 | Takeda Vaccines, Inc. | Method for removing host cell dna from virus preparation |
WO2023147337A2 (en) | 2022-01-25 | 2023-08-03 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
WO2023158989A1 (en) | 2022-02-15 | 2023-08-24 | Takeda Vaccines, Inc. | Dengue vaccine batch mixing process |
WO2023215383A1 (en) | 2022-05-04 | 2023-11-09 | Takeda Vaccines, Inc. | Computer-based determination of flavivirus infectivity |
EP4375381A1 (en) | 2022-11-18 | 2024-05-29 | Takeda Vaccines, Inc. | A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation |
WO2024118740A1 (en) | 2022-11-29 | 2024-06-06 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999061916A1 (en) | 1998-05-29 | 1999-12-02 | Epimmune, Inc. | Identification of broadly reactive dr restricted epitopes |
EP1165127B1 (en) * | 1999-03-26 | 2008-12-31 | Walter Reed Army Institute of Research | Multivalent dengue virus vaccine |
JP2002540171A (ja) | 1999-03-26 | 2002-11-26 | ウォルター リード アーミー インスティテュート オブ リサーチ | 弱毒化デング熱4型ウイルスワクチン |
US6632663B1 (en) | 1999-09-22 | 2003-10-14 | Aventis Pasteur Limited | DNA immunization against chlamydia infection |
EP2278012B1 (en) | 2000-02-16 | 2015-08-26 | The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services | Immunogenic Dengue 2 virus chimeras |
ATE412738T1 (de) | 2000-05-30 | 2008-11-15 | Univ Mahidol | Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen |
EP1159969A1 (fr) * | 2000-05-30 | 2001-12-05 | Aventis Pasteur | Vaccine composition |
AU2003239932A1 (en) | 2002-05-31 | 2003-12-19 | Acambis, Inc. | Tetravalent dengue vaccines |
CN1234852C (zh) * | 2003-01-30 | 2006-01-04 | 上海天甲生物医药有限公司 | 一种以登革热病毒重组复制子为载体的假病毒颗粒疫苗 |
JP4616827B2 (ja) * | 2003-03-24 | 2011-01-19 | ザ スクリプス リサーチ インスティチュート | 腫瘍成長に対するdnaワクチン及びその使用方法 |
EP1893637B1 (en) * | 2005-06-17 | 2016-01-06 | Sanofi Pasteur | Dengue serotype 1 attenuated strain |
WO2006134443A1 (en) * | 2005-06-17 | 2006-12-21 | Sanofi Pasteur | Dengue serotype 2 attenuated strain |
CA2618783A1 (en) * | 2005-08-10 | 2007-02-22 | Acambis Inc. | Vaccination against dengue virus infection |
FR2906724B1 (fr) * | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
FR2909286B1 (fr) * | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
-
2006
- 2006-07-12 FR FR0606324A patent/FR2903605A1/fr not_active Withdrawn
-
2007
- 2007-07-11 KR KR1020097002307A patent/KR20090027759A/ko not_active Application Discontinuation
- 2007-07-11 BR BRPI0712878-9A patent/BRPI0712878A2/pt not_active IP Right Cessation
- 2007-07-11 AR ARP070103083A patent/AR061887A1/es not_active Application Discontinuation
- 2007-07-11 MY MYPI20085395A patent/MY169275A/en unknown
- 2007-07-11 WO PCT/FR2007/051641 patent/WO2008007021A1/fr active Application Filing
- 2007-07-11 JP JP2009518935A patent/JP5295956B2/ja not_active Expired - Fee Related
- 2007-07-11 EP EP07823563A patent/EP2043680A1/fr not_active Withdrawn
- 2007-07-11 AU AU2007274100A patent/AU2007274100B2/en not_active Ceased
- 2007-07-11 ZA ZA200900155A patent/ZA200900155B/xx unknown
- 2007-07-11 CA CA002656349A patent/CA2656349A1/en not_active Abandoned
- 2007-07-11 CN CN2007800263768A patent/CN101489585B/zh not_active Expired - Fee Related
- 2007-07-11 MX MX2009000369A patent/MX2009000369A/es active IP Right Grant
- 2007-07-12 US US11/776,816 patent/US7718357B2/en not_active Expired - Fee Related
- 2007-07-12 TW TW096125447A patent/TWI400333B/zh not_active IP Right Cessation
-
2009
- 2009-01-01 IL IL196331A patent/IL196331A0/en unknown
-
2010
- 2010-03-05 US US12/718,091 patent/US20100221285A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MY169275A (en) | 2019-03-21 |
TWI400333B (zh) | 2013-07-01 |
IL196331A0 (en) | 2011-08-01 |
CN101489585B (zh) | 2013-12-04 |
JP5295956B2 (ja) | 2013-09-18 |
FR2903605A1 (fr) | 2008-01-18 |
TW200813228A (en) | 2008-03-16 |
US20080014219A1 (en) | 2008-01-17 |
US20100221285A1 (en) | 2010-09-02 |
EP2043680A1 (fr) | 2009-04-08 |
AU2007274100B2 (en) | 2013-02-07 |
MX2009000369A (es) | 2009-01-29 |
KR20090027759A (ko) | 2009-03-17 |
US7718357B2 (en) | 2010-05-18 |
ZA200900155B (en) | 2010-03-31 |
CN101489585A (zh) | 2009-07-22 |
CA2656349A1 (en) | 2008-01-17 |
BRPI0712878A2 (pt) | 2012-09-04 |
JP2009542783A (ja) | 2009-12-03 |
WO2008007021A1 (fr) | 2008-01-17 |
AU2007274100A1 (en) | 2008-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR061887A1 (es) | Una composicion de vacuna contra el dengue | |
AR064009A1 (es) | Metodo de inmunizacion contra los 4 serotipos del dengue | |
AR063057A1 (es) | Metodo de inmunizacion contra los 4 serotipos de dengue | |
CY1122291T1 (el) | Αναστολeις ιικου αναδιπλασιασμου | |
ECSP10010106A (es) | Trans-clomifeno para el síndrome metabólico | |
ECSP10010002A (es) | Derivados indólicos 2,3 sustituidos y métodos de uso de los mismos | |
ECSP099792A (es) | Nuevos peptidos inhibidores de la replicacion del virus de hepatitis c | |
ECSP066959A (es) | Compuestos macrociclicos como inhibidores de la replicación viral | |
CL2009002207A1 (es) | Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c. | |
AR055095A1 (es) | Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c | |
CL2012001176A1 (es) | Compuestos derivados de bencimidazol-imidazol, inhibidores del virus de la hepatitis c (hcv); composición farmacéutica que los comprende; combinación farmacéutica; uso en la prevención o tratamiento de infección de hcv. | |
PE20141906A1 (es) | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento | |
PE20060002A1 (es) | Combinaciones antineoplasicas de cci-779 y rituximab | |
ECSP099780A (es) | Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c | |
CO6300964A2 (es) | Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano | |
CL2011000170A1 (es) | Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa. | |
CO6190623A2 (es) | Vacuna salmonella | |
AR078224A1 (es) | Composicon para el tratamiento del cancer de prostata | |
CU20090112A6 (es) | Compuestos macrocíclicos como inhibidores de la replicación viral | |
CL2011000798A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
AR070025A1 (es) | Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica | |
CO2021003931A2 (es) | Dosis unitaria de vacuna contra el dengue y administración de esta | |
CL2011003043A1 (es) | Composicion para proteger sujeto contra serotipo de virus del dengue que comprende al menos dos serotipos de virus dengue; sistema para administrar una composicion de vacuna del dengue; kit de vacuna porque comprende al menos una composicion de vacuna contra el virus del dengue. | |
BRPI0917502A2 (pt) | composição farmacêtica, e, métodos para usar um ácido orgânico ou um antioxidante, para evitar a descoloração causada quando ácido tranemaxâmico e ácido ascórbico são incorporados em uma mesma composição, e para produzir uma preparação farmacêutica sólida para administração oral | |
AR056558A1 (es) | Metodos para estabilizar composiciones oftalmicas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |